Skip to content
Search

Latest Stories

AI algorithm that detects brain defects could help treat hard-to-spot epilepsy

A University College London team of researchers has developed an artificial intelligence (AI) programme that can identify minute brain defects or anomalies that lead to epileptic seizures.

The algorithm, used in the Multicentre Epilepsy Lesion Detection project (MELD) and which reports locations of abnormalities in cases of drug-resistant focal cortical dysplasia (FCD) -- a major cause of epilepsy -- was developed by a multinational team who used more than 1,000 patient MRI scans from 22 international epilepsy centres.


Brain regions known as FCDs have evolved improperly and frequently lead to drug-resistant epilepsy. Surgery is usually used to treat it, however, finding the lesions on an MRI is a constant problem for doctors because MRI scans for FCDs can appear normal.

The scientists employed about 300,000 places throughout the brain to quantify cortical properties from the MRI scans, such as how thick or folded the cortex/brain surface was.

The system was then trained on cases that experienced radiologists had classified as either having FCD or being a healthy brain based on their patterns and attributes.

In general, the algorithm was successful in identifying the FCD in 67 per cent of instances in the cohort, according to the results, which were published in Brain.

Radiologists had previously been unable to uncover the abnormalities in 178 of the patients based on their MRI results; however, the MELD algorithm was able to detect the FCD in 63 per cent of these cases.

This is crucial because, if doctors can identify the anomaly in the brain scan, surgery to remove it could result in a recovery.

A severe neurological illness

Mathilde Ripart, a co-first author from the UCL Great Ormond Street Institute of Child Health, stated: "We focused on developing an AI system that was interpretable and could assist physicians in making decisions. A crucial step in that process was demonstrating to the doctors how the MELD algorithm generated its forecasts.

Dr Konrad Wagstyl, a co-senior author from the UCL Queen Square Institute of Neurology, added: "This algorithm might make it easier to identify these concealed lesions in epileptic children and adults, which would increase the number of patients who could potentially benefit from brain surgery to treat their condition and enhance cognitive function. In England, epilepsy surgery could help about 440 kids a year."

Epilepsy is a severe neurological illness that affects 1 per cent of the world's population and is marked by recurrent seizures.

About 600,000 people in the UK are impacted. The majority of epilepsy patients can be treated with pharmaceuticals, although 20-30 per cent of them do not benefit from them.

FCD is the most frequent cause in children who have had surgery to treat their epilepsy, and it is the third most frequent cause in adults.

Furthermore, FCD is the most frequent reason for epilepsy in people who have a brain anomaly that cannot be seen on an MRI scan.

The 22 hospitals involved in the study used various MRI scanners from around the world, making the algorithm more robust but also perhaps affecting its sensitivity and specificity.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less